+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide



Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide



Circulation 105(20): 2398-2403



Background-The prognosis of patients with severe pulmonary hypertension (PHT) is poor. To determine prognosis and guide therapy, an acute hemodynamic trial of selective pulmonary vasodilators, usually inhaled nitric oxide (iNO), was performed. We hypothesized that oral sildenafil, a phosphodiesterase-5 inhibitor, is a safe and effective alternative to iNO. Methods and Results-We studied 13 consecutive patients (mean+-SEM, 44+-2 years of age; 9 women) referred for consideration of heart-lung transplantation or as a guide to medical therapy. All but one were functional class III or IV. Patients had primary PHT (n=9), pulmonary arterial hypertension (n=2), or secondary PHT (n=2). Hemodynamics and serum cyclic guanosine-monophosphate levels (cGMP) were measured at baseline and at peak effects of iNO (80 ppm), sildenafil (75 mg), and their combination. The decrease in pulmonary vascular resistance was similar with iNO (-19+-5%) and sildenafil (-27+-3%), whereas sildenafil+iNO was more effective than iNO alone (-32+-5%, P<0.003). Sildenafil and sildenafil+iNO increased cardiac index (17+-5% and 17+-4%, respectively), whereas iNO did not (-0.2+-2.0%, P<0.003). iNO increased, whereas sildenafil tended to decrease, pulmonary capillary wedge pressure (+15+-6 versus -9+-7%, P<0.0007). Systemic arterial pressure was similar among groups and did not decrease with treatment. cGMP levels increased similarly with iNO and sildenafil, and their combination synergistically elevated cGMP (P<0.0001). Conclusions-A single oral dose of sildenafil is as effective and selective a pulmonary vasodilator as iNO. Sildenafil may be superior to iNO in that it increases cardiac output and does not increase wedge pressure. Future studies are indicated to establish whether sildenafil could be effective over a longer duration.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011096795

Download citation: RISBibTeXText

PMID: 12021227

DOI: 10.1161/01.cir.0000016641.12984.dc


Related references

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Journal of the American College of Cardiology 39(5 Suppl. A): 224A, 2002

Oral sildenafil is an effective specific pulmonary vasodilator in patients with pulmonary arterial hypertension. Acc Current Journal Review 11(6): 20-0, 2002

Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilatation by inhaled nitric oxide in patients with pulmonary hypertension. Circulation 100(18 Suppl. ): I 240, 1999

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. American Journal of Cardiology 90(6): 677-680, 2002

Acute Hemodynamic Effect Of Sildenafil In Comparison With Inhaled Nitric Oxide In Patients Receiving Bosentan Therapy For Pulmonary Arterial Hypertension. Chest 132(4): 488a-1-488a-2, 2007

Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. Pulmonary Circulation 5(2): 305-312, 2015

Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents. Clinics in Perinatology 39(1): 149-164, 2012

Effect of nebulised iloprost combined with inhaled nitric oxide and oral sildenafil on lung transplant patients. Therapeutic efficacy in pulmonary hypertension during surgery. Revista Espanola de Anestesiologia Y Reanimacion 59(3): 142-149, 2014

Inhaled nitric oxide in primary pulmonary hypertension The Perfect pulmonary vasodilator. Circulation 92(8 Suppl. ): I241, 1995

Sildenafil reduces pressure and pulmonary resistance and increases susceptibility of pulmonary arteries to nitric oxide in primary pulmonary arterial hypertension. Przeglad Lekarski 62(2): 135-138, 2005

Inhaled nitric oxide a selective pulmonary vasodilator for the treatment of persistent pulmonary hypertension of the newborn pphn. Circulation 84(4 Suppl. 2): II321, 1991

Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respiratory Medicine 98(3): 225-234, 2004

Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study. Journal of Neonatal-Perinatal Medicine 9(3): 251-259, 2017

Severe neonatal pulmonary hypertension secondary to antenatal maternal diclofenac ingestion reversed by inhaled nitric oxide and oral sildenafil. Annals of Saudi Medicine 27(6): 448-449, 2007

Prophylactic treatment of oral sildenafil citrate for pulmonary hypertension in an infant treated with inhaled nitric oxide after open-heart surgery. Kyobu Geka. Japanese Journal of Thoracic Surgery 58(13): 1136-1139, 2005